Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ChAd63 and MVA ME-TRAP Malaria Vaccines
NCT03084289Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Mar 2017
- Primary completion
- Jul 2020
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChAd63 ME-TRAP and MVA ME-TRAP in malaria (8 arms), sponsored by University of Oxford. Primary endpoint: Incidence of occurrence of emergent adverse events at 3 months. Started Mar 2017; status: completed.
02
Drugs
ChAd63 ME-TRAPMVA ME-TRAP
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03084289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03084289.